Christoph Gerdes

USPTO Granted Patents = 31 (Patent Applications = 23)

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 15 (Patent Applications = 33)

Average Co-Inventor Count = 12.0

ph-index = 6

Forward Citations = 132(Granted Patents)

Location History:

Leverkusen, DE (1997 - 2012)
Köln, DE (2011 - 2019)
Cologne, DE (2021 - 2024)

Company Filing History:

14 out of 378

Bayer Pharma Aktiengesellschaft

patents

9 out of 12,157

Bayer Aktiengesellschaft

patents

7 out of 721

Bayer Intellectual Property Gmbh

Years Active: 1997-2024

Loading Chart...

31 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11912692 - Substituted S-alaninate derivatives (2024-02-27),

2. 11046783 - Antibodies capable of binding to the coagulation factor XIa and uses thereof (2021-06-29),

3. 10221247 - Antibodies capable of binding to the coagulation factor XIa and uses thereof (2019-03-05),

4. 10183932 - Substituted oxopyridine derivatives and use thereof cardiovascular disorders (2019-01-22),

5. 10077265 - Substituted oxopyridine derivatives (2018-09-18),

6. 10040866 - Nucleic acids and host cells expressing antibodies capable of binding to the coagulation factor XIa and uses thereof (2018-08-07),

7. 9918969 - Substituted oxopyridine derivatives and use thereof as factor XIa/plasma (2018-03-20),

8. 9822102 - Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders (2017-11-21),

9. 9783614 - Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof (2017-10-10),

10. 9765070 - Substituted oxopyridine derivatives (2017-09-19),

11. 9493472 - Substituted benzoxazoles (2016-11-15),

12. 9475809 - Substituted oxopyridine derivatives and use thereof as factor xia/plasma (2016-10-25),

13. 9434690 - Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders (2016-09-06),

14. 8987248 - Substituted piperidines as Par-1 antagonists (2015-03-24),

15. 8846934 - Substituted oxazolidinones and their use (2014-09-30),

Title: Christoph Gerdes: Pioneering Innovation in Köln

Introduction:

Christoph Gerdes is a visionary inventor based in Köln, DE, who continues to inspire the next generation of inventors with his dedication to creating a better future through innovation. With an impressive portfolio of 31 patents, Gerdes is a trailblazer in the field of medical advancements and therapeutic solutions.

Latest Patents:

Among his latest patents are groundbreaking inventions such as Substituted S-alaninate derivatives, which are utilized in the treatment and prophylaxis of vascular disorders, particularly thrombotic or thromboembolic complications. Additionally, his invention of Antibodies capable of binding to the coagulation Factor XIa showcases his expertise in developing agents that inhibit platelet aggregation and prevent thrombus formation.

Career Highlights:

Gerdes has made significant contributions to renowned companies such as Bayer Pharma Aktiengesellschaft and Bayer Aktiengesellschaft. Through his innovative work, he has fueled advancements in the pharmaceutical industry and has set new standards for medical research and development.

Collaborations:

Throughout his career, Gerdes has collaborated with esteemed professionals in the field, including Anja Buchmüller and Susanne Röhrig. These collaborations have led to the creation of cutting-edge solutions that have a profound impact on the medical community and beyond.

Conclusion:

In conclusion, Christoph Gerdes stands as a beacon of innovation, leading the way in creating transformative solutions for complex medical challenges. His visionary approach and unwavering dedication serve as an inspiration for aspiring inventors worldwide, shaping the future of healthcare and beyond.

This text is generated by artificial intelligence and may not be accurate.